Preservative Substances – the Daily Dose of Benzalkonium Chloride in Glaucoma Treatment from the Patient’s Point of View
Authors:
P. Výborný; S. Sičáková; Z. Veselá Flórová
Authors place of work:
Oční klinika JL, Praha, primář MUDr. Ján Lešták, CSc., FEBO
; Oční klinika 1. LF UK a ÚVN – Vojenská fakultní nemocnice, Praha
přednosta doc. MUDr. Jiří Pašta, CSc., FEBO
Published in the journal:
Čes. a slov. Oftal., 70, 2014, No. 3, p. 95-97
Category:
Original Article
Summary
The author calculated the daily dose of Benzalkonium Chloride (BAC) in eye drops used in glaucoma treatment from the patient’s point of view, which means the real amount of BAC applied in the conjunctival sac. The information about BAC concentration in 1 milliliter (mL) do not offer sufficient picture about real circumstances, because the size of the drop, especially after the introducing of the use of generic products in clinical practice in specific anti-glaucomatic drugs, differs significantly. The daily dose of BAC may have substantial significance in the patient’s treatment tolerance. The overview of BAC daily dose in single therapeutic groups and drugs follows: betablockers: Timo-COMOD 0, Arutimol 2.6, Vistagan 2.8, Timolol-POS 3.0, Arteoptic 3.7, Betoptic S 4.8, Timoptol MSD 6.3, Betoptic 10.0; alpha-mimetics: Alphagan 3.5, Luxfen 3.5, Aruclonin 7.1; derivates of prostaglandine, prostamides: Taflotan 0, Monopost 0, Lumigan 1.4, Unilat 3.1, Travatan 3.9, Latanoprost Apotex 4.3, Rescula 5.8, Latanoprost POS 5.9, Xalatan 6.0, Latanoprost Ratiopharm 6.0, Latanoprost Actavis 6.0, Latanoprost Arrow 6.0, Arulatan 5.4, Latalux 6.0, Glaucotens 6.0, Xaloptic 6.0, Solusin 6.1; carboanhydrase inhibitors: Batidor 3.8, Azopt 4.8, Trusopt 5.4, Oftidor 8.1; fixed combinations: Ganfort 1.4, Dorzolamid/timolol TEVA 2.8, Combigan 3.2, Duotrav 4.3, Cosopt 5.6, Xalacom 6.0, Glaucotima 6.0, Latanoprost/timolol Apotex 6.3, Azarga 6.4, Dorzogen Combi 6.5, and Dozotima 8.8 µl.
Key words:
glaucoma, antiglaucomatic treatment, preservatives, Benzalconium Chloride, BAC, daily dose of BAC
Zdroje
1. Ammar, D.A., Noecker, R.J., Kahook, M.Y.: Effects of benzalkonium chloride-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells. Advances in Therapy, 27; 2010: 837–845.
2. Anvar, Z., Wellik, S.R., Galor, A.: Glaucoma therapy and ocular surface disease. Curr Opin Ophthalmol, 24; 2013: 136–143.
3. Baudoin, C.: Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol, 7; 1996: 80–86.
4. Baudoin, C., Abbé, A., Liang, H., et al.: Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res, 29; 2010: 312–334.
5. Brasnu, E., Brignole-Baudoin, F., Riancho, L. et al.: In vitro effects of preservative-free tafluprost and preserved latanoprost, and bimatoprost in a conjunctival epithelial cell line. Curr Eye Res, 27; 2008: 303–312.
6. Cantor, L.B., Liu, C.C., Batoosingh, A.L., et al.: Safety and tolerability of brimonidine purite 0,1% and brimonidine 0,15%: a meta-analysis of the phase 3 studies. Curr Med Res Opin, 25; 2009: 1615–1620.
7. Hopes M, Broadway D.: Preservative-free treatment in glaucoma is a sensible and realistic aim for the future. European Ophthalmic Review, 4, 2010: 23–28.
8. Kahook,M.Y., Noecker, R.: Quantitative analysis of conjunctival goblet cells after chronic application of topical drugs. Adv Ther, 25; 2008: 743–751.
9. Karhanová, M., Mlčák, P., Fryšák, Z., et al.: Účinnost a snášenlivost tafluprostu 0,0015% bez konzervačních látek v léčbě glaukomu a oční hypertenze. Čes a Slov Oftal, 68; 2012: 150–155.
10. Lewis, R.A., Katz, G., Weiss, M.J., et al.: Travoprost 0,004% with and without benzalkonium chloride: a comparisosn of safety and efficacy. J Glaucoma, 16, 2007: 98–103.
11. Noecker, R., Miller, K.V.: Benzalkonium chloride in glaucoma medications. Ocul Surf, 9; 2011: 159–162.
12. Pisella, P. J., Pouliquen, P., Baudoin, C.: Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol, 86; 2002: 418–423.
13. Ryan, G. Jr., Fain, J.M., Lovelace, C., et al.: Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0,02% benzalkonium chloride and travoprost with the sofZia preservative system. BMC Ophthalmology, 21, 2011, 11:8, doi 10.1186/1471-2415-11-8, dostupné na http://www.biomedcentral. com/1471-2415/11/8.
14. Tressler, C. S., Beatty, R., Lemp, M.A.: Preservative use in topical glaucoma medications. Ocul Surf, 9; 2011: 140–158.
15. Valente, C., Iester, M.: Impact of glaucoma medication on ocular tissue. Expert Rev Ophthalmol, 5; 2010: 405–412.
16. Výborný, P., Sejčková, L.: Antiglaukomatika – obsah konzervačních látek a spolupráce pacienta v léčebném režimu. Čes a Slov Oftal, 62; 2006: 270–274.
17. Výborný, P., Sičáková, S.: Denní dávka benzalkonium chloridu – významné kritérium v léčbě glaukomu. Čes a Slov Oftal, 67; 2011: 63–66.
18. Výborný, P., Sičáková, S., Dohnalová, P., et al.: Terapie glaukomu – aktuální přehled dat a informací. Čes a Slov Oftal, 69; 2013: 118–126.
19. Yee, R.W.: The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Current Opinion in Ophthalmol, 18; 2007: 134–139.
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2014 Číslo 3
Najčítanejšie v tomto čísle
- Internal Limiting Membrane Peeling as Prophylaxis of Epimacular Membrane Formation in Eyes Undergoing Vitrectomy for Rhegmatogenous Retinal Detachement
- Surgical Treatment of Severe Degree of Ptosis of the Upper Eyelid Using a Fronto-tarsal Sling of Biocompatible PVC
- Rare Ocular Manifestation with Suspect Alport Syndrome
- Preservative Substances – the Daily Dose of Benzalkonium Chloride in Glaucoma Treatment from the Patient’s Point of View